Company Overview

Company name: Scythian Biosciences (CNQ: SOL)
Description: Operator of a pre-clinical research and development company that is in the process of developing drug therapies. The company intends to develop other potential cannabinoid and non-cannabinoid based pharmaceutical products, including one that is in development for the treatment of gastro-inflammatory disease. Its first project underway is the development of a proprietary cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury.
Year founded: 2005
Parent company:
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
Employees: 11
City: Toronto
State: Ontario
Country: Canada
Region: Americas

Financial Highlights

Start up capital raised (USD Million): 0.26
Business status: Pre-Clinical Trials
Ownership: Publicly Held
Exchange: CNQ
Ticker: SOL
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million) -0.05
Enterprise value: 1.64
Earnings before interest, tax, depreciation and amortization (EBITDA): -0.05
Fiscal period: TTM 1Q2017
Financing Status: The company raised CAD 12.5 million in its second public offering on the TSX Venture Exchange under the ticker symbol of SCYB on February 6, 2018. A total of 672,125 shares were sold at CAD 18.6 per share. The underwriters were granted an option to purchase up to an additional 100,818 shares from the company to cover over-allotments, if any.
Number of active investors:
Profile last updated: 30-Oct-2018
Last known valuation:
Last known valuation date: